Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Abivax
Abivax
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Recruitment
Abivax strengthens its management team
Regulatory
ABIVAX’s ABX464 reduces HIV reservoir in blood in second phase clinical trial
ABX464 is the first drug candidate to show statistically significant (p<0.01) reduction of the HIV viral reservoir
Research & Development
Evotec and ABIVAX collaborate to develop novel antiviral agents
Evotec and ABIVAX have announced a strategic collaboration to discover and develop novel treatments for multiple viral infectious diseases
Regulatory
First ever evidence of treatment-induced reduction in HIV reservoirs
Preliminary clinical trial results support ABX464's potential to become a key functional cure element for HIV
Manufacturing
Abivax enters into a manufacturing agreement with PCAS for ABX464
Collaboration ensures drug candidate supply for upcoming clinical trials
Research & Development
Abivax makes three new personnel changes
Including the appointment of a new Chief Medical Officer
Pharmaceutical
Abivax makes two appointments to executive management team
Karl Birthistle joins as VP of Global Regulatory Affairs, while Daniel Kenny becomes VP of Business Development
Subscribe now